GSC
SNOA icon

Ground Swell Capital’s Sonoma Pharmaceuticals SNOA Stock Holding History

Ground Swell Capital’s Portfolio SNOA Stock Details SNOA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-10,400
Closed -$31.9K – 249
2024
Q3 		$31.9K Buy
+10,400
New +$53.1K 0.03% 114
2023
Q2 		– Sell
-666
Closed -$13K – 88
2023
Q1 		$13K Buy
+666
New +$17.2K 0.02% 47

Other funds holding SNOA

UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
US Bancorp
US Bancorp Minneapolis, Minnesota $91.6B AUM 29.2% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
AF
Allworth Financial Folsom, California $23.6B AUM 20.99% 1-Year Est. Return
DB
Danske Bank Copenhagen K, Denmark $50.6B AUM 42.84% 1-Year Est. Return

Ground Swell Capital's SNOA Position: Q4 2024 in Review

Ground Swell Capital sold out of Sonoma Pharmaceuticals (SNOA) in Q4 2024, closing a stake of 10,400 shares — an estimated $31.9K sold.

Ground Swell Capital first reported a position in SNOA in Q1 2023 and held it in 2 quarters. The position peaked at $31.9K in Q3 2024. 9 funds tracked by Wall St. Rank hold SNOA as of Q4 2024.

  • Ground Swell Capital reported no remaining Sonoma Pharmaceuticals position as of Q4 2024 after selling out during the quarter.
  • Ground Swell Capital sold 10,400 Sonoma Pharmaceuticals shares in Q4 2024, an estimated $31.9K.
  • Ground Swell Capital first reported a position in Sonoma Pharmaceuticals in Q1 2023 and held it in 2 quarters.
  • Ground Swell Capital's Sonoma Pharmaceuticals position peaked at $31.9K in Q3 2024.
  • 9 funds tracked by Wall St. Rank held Sonoma Pharmaceuticals as of Q4 2024.

Based on Ground Swell Capital's 13F filing for Q4 2024, filed 14 Feb 2025.